Inhalation Sciences Sweden Future Growth

Future criteria checks 2/6

Inhalation Sciences Sweden is forecast to grow revenue at 59.5% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth	45.2%
Revenue growth rate	59.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	29 Feb 2024

Recent future growth updates

Recent updates

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Dec 29

Earnings and Revenue Growth Forecasts

NGM:ISAB - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	66	N/A	N/A	N/A	1
12/31/2024	38	N/A	N/A	5	1
12/31/2023	18	-5	-4	-4	N/A
9/30/2023	17	-5	-4	-4	N/A
6/30/2023	15	-7	-3	-3	N/A
3/31/2023	13	-11	-6	-6	N/A
12/31/2022	12	-12	-12	-12	N/A
9/30/2022	12	-14	-14	-14	N/A
6/30/2022	12	-15	-17	-17	N/A
3/31/2022	9	-17	-19	-19	N/A
12/31/2021	9	-17	-19	-19	N/A
9/30/2021	7	-18	-18	-18	N/A
6/30/2021	6	-16	-13	-13	N/A
3/31/2021	7	6	-9	-9	N/A
12/31/2020	10	10	-6	-5	N/A
9/30/2020	12	12	-7	-6	N/A
6/30/2020	14	12	-11	-9	N/A
3/31/2020	14	-1	-12	-9	N/A
12/31/2019	9	-4	-12	-9	N/A
9/30/2019	9	-3	-12	-9	N/A
6/30/2019	8	-3	-13	-11	N/A
3/31/2019	6	-11	-11	-10	N/A
12/31/2018	5	-12	-11	-10	N/A
9/30/2018	5	-12	-7	-7	N/A
6/30/2018	6	-10	-6	-6	N/A
3/31/2018	7	-9	-5	-5	N/A
12/31/2017	8	-6	-7	-7	N/A
9/30/2017	6	-7	N/A	-6	N/A
6/30/2017	6	-7	N/A	-6	N/A
3/31/2017	8	-6	N/A	-6	N/A
12/31/2016	10	-5	N/A	-6	N/A
12/31/2015	10	-3	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ISAB's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if ISAB's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if ISAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ISAB's revenue (59.5% per year) is forecast to grow faster than the Swedish market (1.6% per year).

High Growth Revenue: ISAB's revenue (59.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ISAB's Return on Equity is forecast to be high in 3 years time

Inhalation Sciences Sweden Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

Recent updates

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

New major risk - Share price stability

Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023

New major risk - Revenue and earnings growth

Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022)

Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021)

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US

Inhalation Sciences Announces Positive Study Results

Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020)

Investor sentiment improved over the past week

Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial

Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale

Investor sentiment improved over the past week

First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020)

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

New 90-day low: kr10.30

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Market bids up stock over the past week

Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna

New 90-day low: kr10.80

Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies